TwinBeech Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

TwinBeech Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.1M	Buy	90,006 +37,106	+70%	+$806K	0.22%	141
2025 Q4	$1.11M	Buy	52,900 +8,606	+19%	+$150K	0.08%	284
2025 Q3	$681K	Sell	44,294 -68,500	-61%	-$897K	0.03%	361
2025 Q2	$1.06M	Sell	112,794 -143,038	-56%	-$1.57M	0.02%	410
2025 Q1	$3.14M	Sell	255,832 -100,068	-28%	-$1.41M	0.06%	324
2024 Q4	$4.7M	Buy	355,900 +157,321	+79%	+$2.69M	0.08%	228
2024 Q3	$3.82M	Buy	198,579 +30,865	+18%	+$638K	0.07%	300
2024 Q2	$3.44M	Buy	167,714 +95,831	+133%	+$2.01M	0.07%	267
2024 Q1	$1.71M	Sell	71,883 -11,573	-14%	-$258K	0.04%	361
2023 Q4	$1.8M	Sell	83,456 -104,654	-56%	-$1.61M	0.03%	415
2023 Q3	$2.73M	Buy	188,110 +37,914	+25%	+$717K	0.05%	363
2023 Q2	$3.14M	Buy	150,196 +20,672	+16%	+$430K	0.06%	324
2023 Q1	$2.74M	Buy	+129,524	New	+$3.22M	0.06%	330

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

TwinBeech Capital's SNDX Position: Q1 2026 in Review

TwinBeech Capital increased its Syndax Pharmaceuticals (SNDX) stake by 70% in Q1 2026, buying an estimated $806K and bringing the position to 90,006 shares worth $2.1M. The position accounts for 0.22% of the portfolio, ranked #141.

TwinBeech Capital first reported a position in SNDX in Q1 2023 and has held it in 13 quarters since. The position peaked at $4.7M in Q4 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

TwinBeech Capital held 90,006 shares of Syndax Pharmaceuticals worth $2.1M as of Q1 2026.
TwinBeech Capital bought 37,106 Syndax Pharmaceuticals shares in Q1 2026, an estimated $806K.
Syndax Pharmaceuticals made up 0.22% of TwinBeech Capital's portfolio in Q1 2026, its #141 holding.
TwinBeech Capital first reported a position in Syndax Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
TwinBeech Capital's Syndax Pharmaceuticals position peaked at $4.7M in Q4 2024.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.